NCT03829839View on ClinicalTrials.gov

Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 3, 2016

Primary Completion Date

August 16, 2017

Study Completion Date

August 16, 2017

Conditions
Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs
Interventions
DRUG

Oxytocin

Intranasal administration, 24 international units (IU) oxytocin

DRUG

Lorazepam 1 mg

Oral administration of 1mg lorazepam

DRUG

Placebo nasalspray

The placebo nasalspray contain identical ingredients except for the active agent itself.

DRUG

Placebo Oral Tablet

The placebo pill contain identical ingredients except for the active agent itself.

Trial Locations (1)

53105

Department of Psychiatry, University of Bonn, Bonn

All Listed Sponsors
lead

University Hospital, Bonn

OTHER

NCT03829839 - Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity | Biotech Hunter | Biotech Hunter